Burning Rock Biotech Ltd (BNR) - Total Liabilities
Based on the latest financial reports, Burning Rock Biotech Ltd (BNR) has total liabilities worth $285.29 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BNR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Burning Rock Biotech Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Burning Rock Biotech Ltd's total liabilities have evolved over time, based on quarterly financial data. See Burning Rock Biotech Ltd (BNR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Burning Rock Biotech Ltd Competitors by Total Liabilities
The table below lists competitors of Burning Rock Biotech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunshine Metals Ltd
AU:SHN
|
Australia | AU$2.43 Million |
|
Asetek A/S
F:A31
|
Germany | €35.78 Million |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $7.56 Million |
|
Chin Hung Int'
KO:002780
|
Korea | ₩322.19 Billion |
|
Pesona Metro Holdings Bhd
KLSE:8311
|
Malaysia | RM652.55 Million |
|
Ramssol Group Bhd
KLSE:0236
|
Malaysia | RM52.71 Million |
|
Netanel Group
TA:NTGR
|
Israel | ILA1.48 Billion |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
China | CN¥5.71 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Burning Rock Biotech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Burning Rock Biotech Ltd (BNR) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Burning Rock Biotech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Burning Rock Biotech Ltd (2017–2025)
The table below shows the annual total liabilities of Burning Rock Biotech Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $285.29 Million | -6.30% |
| 2024-12-31 | $304.48 Million | +12.11% |
| 2023-12-31 | $271.59 Million | -36.71% |
| 2022-12-31 | $429.13 Million | -0.96% |
| 2021-12-31 | $433.28 Million | +79.02% |
| 2020-12-31 | $242.02 Million | -86.08% |
| 2019-12-31 | $1.74 Billion | +78.16% |
| 2018-12-31 | $976.14 Million | +321.03% |
| 2017-12-31 | $231.85 Million | -- |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction test… Read more